Published in Pharma Law Weekly, May 23rd, 2006
Preotact is the European brand name for PREOS which NPS licensed to Nycomed in 2004 for development and marketing in Europe.
The EMEA approved Preotact for treatment of postmenopausal women with osteoporosis at high risk for fractures. More information will be available in the coming days on the EMEA website at www.emea.eu.int.
"We congratulate Nycomed on reaching this major milestone and look forward to the launch of Preotact in Europe...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.